Glucose intolerance in the carcinoid syndrome.
We assayed glucose tolerance and insulin secretion in ten patients with metastatic carcinoid tumors and the carcinoid syndrome ("active tumors") and in seven patients with metastatic carcinoid tumors without the carcinoid syndrome ("inactive tumors"). The patients with "active tumors" had elevated serum serotonin levels while the patients with "inactive tumors" had normal serum serotonin levels. Of the ten patients with "active tumors," five had diabetic and three had borderline intravenous glucose disposal rate constants (KG = 0.88 +/- 0.07, M. +/- S.E.M.). Their KG was significantly lower (p less than 0.01) than a group of age-matched normals. All of the patients with "inactive tumors" had normal KG values (KG = 1.67 +/- 0.24). Their KG did not differ from that of age-matched normal subjects. Both groups of carcinoid patients had a comparable decrease in their insulinogenic index. Two days' administration of the serotonin antagonist cyproheptadine (Cypro) to eight of the patients with "active tumors" resulted in a significant increase in the "insulinogenic index" (50%) but a nonsignificant increase in the KG (12%). Administration of p-chlorophenylalanine, a compound that blocks serotonin synthesis, resulted in an increase in both the KG (60%) and the "insulinogenic index" (55%). The insulin half-life (t1/2) of patients with "active tumors" (6.1 +/- 0.4 min.) did not differ from the t1/2 of normal subjects (6.6 +/- 0.4 min.), suggesting that the decreased plasma insulin levels following intravenous glucose were due to impaired insulin secretion rather than accelerated insulin destruction. Seven of the patients received treatment with the antitumor agent streptozotocin (Strepto). The patients received cumulative doses of from 70 to 300 mg. of Strepto per kilogram body weight with no impairment in glucose tolerance or insulin secretion. We conclude that there is high incidence of glucose intolerance (80%) and impaired insulin secretion in patients with the carcinoid syndrome and that serotonin plays a role in producing these alterations.
D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D003533:Cyproheptadine / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000378:metabolism; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism* / Q000494:pharmacology; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood / Q000502:physiology*; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000378:metabolism; D008659:Metabolic Diseases / Q000150:complications*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012701:Serotonin / Q000097:blood; D013311:Streptozocin / Q000627:therapeutic use
D007328:Insulin; D003533:Cyproheptadine; D012701:Serotonin; D013311:Streptozocin; D005947:Glucose; D010134:Fenclonine